X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling - PubMed (original) (raw)
Comparative Study
. 1993 Feb 20;229(4):969-95.
doi: 10.1006/jmbi.1993.1099.
Affiliations
- PMID: 8095303
- DOI: 10.1006/jmbi.1993.1099
Comparative Study
X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling
C Eigenbrot et al. J Mol Biol. 1993.
Abstract
The X-ray structures of 1 Fv and 2 Fab humanized anti-p185HER2 antibody fragments (IgG1-kappa) have been determined at a resolution between 2.7 A and 2.2 A. The antibodies are three different versions of a human antibody framework onto which the antigen recognition loops from a murine antibody (4D5) have been grafted. The sequences of the three versions differ in the framework region at positions L55, H78 and H102. The version 8 Fv fragment crystallizes in space group P2(1) with cell parameters a = 37.6 A, b = 63.4 A, c = 90.2 A, beta = 98.2 degrees, with two molecules per asymmetric unit, and has been refined against data 10.0 A-2.2 A to an R-factor of 18.3%. Versions 4 and 7 Fabs crystallize in space group P1 with cell parameters a = 39.2 A, b = 80.2 A, c = 86.1 A, alpha = 113.1 degrees, beta = 92.7 A, gamma = 102.6 A and two molecules per asymmetric unit. Version 4 has been refined against data 10.0 A-2.5 A resolution to an R-factor of 17.9%. Version 7 has been refined against data 10 A-2.7 A to an R-factor of 17.1%. The X-ray structures have been used to assess the accuracy of structural predictions made via molecular modeling, and they confirm the structural role of certain framework residues and the conformations of five of six complementarity determining regions (CDRS). The average deviation of the model from the X-ray structures is within the range observed among the X-ray structures for 81% of the C alpha atoms. Of the hydrogen bonds common to the X-ray structures, 94% of the main-chain-main-chain and 79% of the main-chain-side-chain ones were predicted by the model. The side-chain conformation was predicted correctly for 79% of the buried residues. The third CDR in the heavy chain is variable, differing by up to 8 A between molecules within an asymmetric unit. The structural relationship between variable domains of light and heavy chains is not significantly altered by the absence of constant domains in the Fv molecule. The antigen-binding potential of an unusual light chain sequence has been confirmed. The arginine at position 66 interacts with the first light chain CDR, but in a fashion somewhat different than predicted. A substitution of a leucine for an alanine side-chain directed between the beta-sheets has only relatively small and local effects.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC, Shan L, Goldsteen BZ, Guddat LW, Thakur A, Landolfi NF, Co MS, Vasquez M, Queen C, Ramsland PA, Edmundson AB. Fan ZC, et al. J Mol Recognit. 1999 Jan-Feb;12(1):19-32. doi: 10.1002/(SICI)1099-1352(199901/02)12:1<19::AID-JMR445>3.0.CO;2-Y. J Mol Recognit. 1999. PMID: 10398393 Review. - The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model.
Essen LO, Skerra A. Essen LO, et al. J Mol Biol. 1994 Apr 29;238(2):226-44. doi: 10.1006/jmbi.1994.1284. J Mol Biol. 1994. PMID: 8158652 - X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65.
Eigenbrot C, Gonzalez T, Mayeda J, Carter P, Werther W, Hotaling T, Fox J, Kessler J. Eigenbrot C, et al. Proteins. 1994 Jan;18(1):49-62. doi: 10.1002/prot.340180107. Proteins. 1994. PMID: 7908437 - The structural basis of antigen-antibody recognition.
Mariuzza RA, Phillips SE, Poljak RJ. Mariuzza RA, et al. Annu Rev Biophys Biophys Chem. 1987;16:139-59. doi: 10.1146/annurev.bb.16.060187.001035. Annu Rev Biophys Biophys Chem. 1987. PMID: 2439094 Review.
Cited by
- Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.
Go EB, Lee JH, Cho JH, Kwon NH, Choi JI, Kwon I. Go EB, et al. J Biol Eng. 2024 Apr 4;18(1):23. doi: 10.1186/s13036-024-00418-3. J Biol Eng. 2024. PMID: 38576037 Free PMC article. - Thermal Stability Estimation of Single Domain Antibodies Using Molecular Dynamics Simulations.
Bekker GJ, Kamiya N. Bekker GJ, et al. Methods Mol Biol. 2023;2552:151-163. doi: 10.1007/978-1-0716-2609-2_8. Methods Mol Biol. 2023. PMID: 36346591 - Computation-Aided Design of Albumin Affibody-Inserted Antibody Fragment for the Prolonged Serum Half-Life.
Kwon NH, Lee JH, Kwon I. Kwon NH, et al. Pharmaceutics. 2022 Aug 24;14(9):1769. doi: 10.3390/pharmaceutics14091769. Pharmaceutics. 2022. PMID: 36145517 Free PMC article. - Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration.
Gerhardy S, Ultsch M, Tang W, Green E, Holden JK, Li W, Estevez A, Arthur C, Tom I, Rohou A, Kirchhofer D. Gerhardy S, et al. Nat Commun. 2022 Sep 5;13(1):5222. doi: 10.1038/s41467-022-32760-9. Nat Commun. 2022. PMID: 36064790 Free PMC article. - Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources